FY2028 Earnings Forecast for TSE:PRN Issued By Raymond James

Profound Medical Corp. (TSE:PRN) – Equities researchers at Raymond James issued their FY2028 EPS estimates for shares of Profound Medical in a research note issued on Thursday, November 7th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings per share of $4.11 for the year. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share.

Profound Medical Price Performance

Shares of Profound Medical stock opened at C$11.32 on Monday. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. The firm’s 50-day simple moving average is C$10.73 and its 200-day simple moving average is C$11.55. Profound Medical has a twelve month low of C$9.55 and a twelve month high of C$16.00. The firm has a market cap of C$277.11 million, a P/E ratio of -6.82 and a beta of 0.81.

Insiders Place Their Bets

In other Profound Medical news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of the stock in a transaction dated Thursday, August 15th. The stock was bought at an average price of C$12.85 per share, for a total transaction of C$125,480.25. Insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.